Teva Pharmaceuticals Industries' (TEVA) US affiliate, Teva Pharmaceuticals, said Monday that its biosimilar Epysqli, developed in collaboration with Samsung Bioepis, is now available in the US to treat rare conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.

Epysqli was approved by the US Food and Drug Administration last year, and it will be priced 30% below Soliris, the brand-name equivalent, Teva said.

The FDA has provisionally determined that Epysqli will be interchangeable with Soliris once the first interchangeable biosimilar's exclusivity period expires, the company said.

Shares of the company were up more than 4% in recent Monday premarket activity.